May 3, 2018 / 6:11 AM / 2 months ago

BRIEF-Cellectis Submits Investigational New Drug Application To FDA For UCART22

May 3 (Reuters) - CELLECTIS SA:

* SAID ON WEDNESDAY IT HAS SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE US FDA REQUESTING APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCART22

* UCART22 IS CO’S SECOND WHOLLY CONTROLLED TALEN® GENE-EDITED PRODUCT CANDIDATE FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN ADULT PATIENTS

* PENDING REGULATORY CLEARANCE, CELLECTIS PLANS TO INITIATE A PHASE I CLINICAL TRIAL IN Q3 2018

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below